Revolutionizing Discovery of Aptamer Therapeutics

SELEX Platform 2.0

...

 Reducing SELEX cycles

 Increasing success rate

 No Lead-optimization

Characteristics of Therapeutic Aptamers

  • Targets extracellular proteins
  • High affinity (KD = pM-nM)
  • Ability to disrupt protein:protein interactions
  • Typically 15-40 nucleotides (5-15 KDa) in length
  • Readily scalable chemical manufacturing process
  • Amenable to post synthesis conjugation (toxin, RNAi, CpG molecules etc)
  • Tunable in vivo stability (t½ from minutes to days)
  • Thermostable and nuclease resistant
  • Reversal agent readily available
  • Non-immunogenic
  • Clinically validated
...

Aptamer Discovery Technology Timeline

...
...

Contact

© 2021 Guardian Therapeutics. All rights reserved.

Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:
info@guardian-rx.com

Business Development Inquiries: businessdevelopment@guardian-rx.com